Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

RSS » New York Times News » NYTHealth

Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys​

July 23, 2025

18-fda-duchenne-mediumSquareAt3X-NJMqB0-rss

 The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Elevidys, after three patients died from liver failure after taking it or a similar treatment.  

Creator: The New York Times (NYTHealth)

Source URL

Related Posts

  • Educational Resources
Black Death Pandemic History: Lessons for Global Health
Black Death pandemic history
  • Outbreaks and Emerging Issues
Pneumonic Plague in Arizona: What You Need to Know
Pneumonic Plague in Arizona
  • Sustainable Practices
Common Forest Management Methods for a Healthy Future
Common forest management methods

Most Recent

  • Book and Article Reviews
One Health Book Review: A Comprehensive Analysis 
One Health Book Review
  • Careers
Value of MPH in One Health: Career Benefits and Impact
Value of MPH in One Health
  • Community Stories
Malaria Control Strategies: One Health in Action
Malaria Control Community Stories

Spheres of Focus

Infectious Diseases

Climate & Disasters

Food &
Water

Natural
Resources

Built
Environments

Technology & Data

Featured Posts

One Health,
One Society:
Bridging Disciplines
for a Healthier World

MENU

NEWSLETTER

Subscribe to our newsletter and stay up to date with all events coming straight in your mailbox:

FOLLOW US

Facebook X-twitter Instagram Linkedin
Copyright © 2025 BioUnison LLC, All Rights Reserved.
One Health Society: A BioUnison Initiative
Privacy Policy | Terms of use